唑来膦酸联合同期放化疗治疗晚期乳腺癌合并骨转移的效果

Effect of zoledronic acid combined with concurrent chemoradiotherapy on advanced breast cancer with bone metastases

目的探讨唑来膦酸联合同期放化疗治疗晚期乳腺癌合并骨转移的临床效果。方法选择2018年1月至2019年1月于我院实施放化疗的30例晚期乳腺癌合并骨转移患者(对照组)与实施唑来膦酸联合同期放化疗的30例晚期乳腺癌合并骨转移患者(观察组)进行回顾性分析。比较两组的疾病控制率、血清钙、血管内皮生长因子(VEGF)、血清肿瘤标志物水平、骨痛程度、癌因性疲乏程度、睡眠质量、生存质量和不良反应发生情况。结果观察组的疾病控制率为83.33%,高于对照组的56.67%(P<0.05)。治疗后,两组的血清钙、VEGF水平均较治疗前显著降低,且观察组低于对照组(P<0.05)。治疗后1、3个月,观察组的癌胚抗原、糖类抗原125、糖类抗原153水平和VAS、癌因性疲乏、PSQI评分均低于对照组,生存质量各项评分均高于对照组(P<0.05)。两组的各项不良反应发生率无显著差异(P>0.05)。结论唑来膦酸联合同期放化疗可有效提高晚期乳腺癌合并骨转移患者的病情控制效果,延缓肿瘤进展,减轻骨痛症状,且安全性良好。

Objective To explore the clinical effect of zoledronic acid combined with concurrent chemoradiotherapy in the treatment of advanced breast cancer with bone metastases.Methods From January 2018 to January 2019,30 cases of advanced breast cancer with bone metastasis who received chemoradiotherapy in our hospiatl(control group)and 30 cases of advanced breast cancer with bone metastasis who received zoledronic acid combined with concurrent chemoradiotherapy(observation group)were selected for retrospectively analyze.The disease control rate,serum calcium,vascular endothelial growth factor(VEGF),serum tumor markers,degree of bone pain,degree of cancer-related fatigue,sleep quality,quality of life and adverse reactions were compared between the two groups.Results The disease control rate of the observation group was 83.33%,which was higher than 56.67% of the control group(P<0.05).After treatment,the serum calcium and VEGF levels in the two groups were significantly lower than those before treatment,and those of the observation group were lower than the control group(P<0.05).At 1 and 3 months after treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 153 and scores of VAS,cancer-related fatigue and PSQI in the observation group were lower than those in the control group,while the scores of quality of life were higher than those in the control group(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Zoledronic acid combined with concurrent chemoradiotherapy can effectively raise the disease control effect,delay tumor progression,and relieve bone pain symptoms of patients with advanced breast cancer with bone metastases,with good safety.